(原标题:礼来出手!泽安全球首创的“髓系细胞衔接器”平台开拓自免治疗新方向)泽安生物医药全球首创(First-in-Class)的“髓系细胞衔接器”免疫治疗平台与礼来世界级的研发和商业化经验“强强联手”,开拓自身免疫性疾病的免疫治疗新方向。2025年7月29日,泽安生物医药(LTZ Therapeutics,以下简称“LTZ”或“公司”)宣布,与国际医药巨头礼来(Eli Lilly and ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.